A study showed that Thalidomide could significantly improve the survival of bone-marrow cancer patients. Researchers found that adding Thalidomide to their standard treatment added an average of 18 months to the lives of elderly patients with multiple myeloma.
Source: The Telegraph:”Thalidomide: Timeline of a Scandal”, September 1, 2012.